The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for Ocugen’s OCU300 (brimonidine tartrate) to treat patients with ocular graft versus host disease (oGVHD).

Ocugen is a clinical stage biopharmaceutical company that focuses on the development of new treatments for sight-threatening diseases.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

oGVHD is a common complication found in 40% to 60% of patients who have undergone allergenic haematological stem cell transplantation (allo-SCT) or bone marrow transplants.

The disease is driven by autoimmune inflammation and causes serious ocular surface disease, which over time declines the quality of the patient’s life significantly and hinders daily activities due to visual impairment.

"We are very excited to receive the first ever orphan drug designation by the FDA for oGVHD, emphasising the unmet medical need for patients with this disease."

OCU300 is a re-purposed drug that is currently being developed through the FDA's 505(b)(2) pathway for the treatment of oGVHD.

Ocugen chairman, co-founder and CEO Dr Shankar Musunuri said: “We are very excited to receive the first ever orphan drug designation by the FDA for oGVHD, emphasising the unmet medical need for patients with this disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This is a significant milestone that will allow us to further advance the clinical development of OCU300, with a proprietary nanoemulsion, into a phase III clinical trial in the near future.”

A post-hoc analysis of OCU300 conducted in an exploratory observational study showed the treatment’s beneficial effect in nearly 90% of oGVHD patients without causing any significant side effects.

Last year, the biopharmaceutical company entered an exclusive worldwide licence agreement with the University of Illinois for OCU300.